Market news

Axsome Therapeutics (NASDAQ:AXSM) has outperformed the market over the past 10 years by 24.39% on an annualized basis producing an average annual return of 37.87%. Currently, Axsome Therapeutics has a market

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in Alzheimer’s disease agitation, while management expects operating expenses to remain relatively stable in the

Axsome Therapeutics (NASDAQ:AXSM) executives highlighted growth across its commercial portfolio, an expanded sales force and multiple late-stage clinical programs during the H.C. Wainwright 28th Annual Global Investment Conference. Chief Operating Officer Mark Jacobson said the company has three ma

Axsome Therapeutics (NasdaqGM:AXSM) reported new clinical data in major depressive disorder and Alzheimer’s disease agitation at a leading psychiatry congress. The presentations focused on key programs in Axsome’s central nervous system pipeline aimed at treating mood and neuropsychiatric symptoms. Management highlighted how the new findings may inform future study designs and regulatory interactions for these indications. These fresh data in depression and Alzheimer’s agitation only capture...

Or are its best days in the rearview mirror?

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data in major depressive disorder and Alzheimer’s disease agitation and eight additional encore data posters spanning its psychiatry and neurology portfolio at Psych Congress 2026, being held September 15-19, in New Orleans, Louisiana. Details of the data presentations

Detailed price information for Ocugen Inc (OCGN-Q) from The Globe and Mail including charting and trades.

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Detailed price information for Envista Holdings Corp (NVST-N) from The Globe and Mail including charting and trades.

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Fireside Chat: Wednesday, September 9, 2026, at 3:45 p.m. ET in Boston, MA 2026 Cantor Global Healthcare Conference Fireside Chat: Thursday, September 10, 2026

Axsome Therapeutics' (AXSM) Auvelity could drive revenue beats for the company, after the therapy's

Axsome Therapeutics (AXSM) said Monday that it has dosed the first patient in its phase 3 trial eval

The company has also crushed broader equities over the past five years.

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Axsome Therapeutics earnings event and why it matters Axsome Therapeutics (AXSM) just reported second quarter 2026 results, with revenue of US$218.38 million and a net loss of US$51.31 million. Earnings per share were a loss of US$0.99, matching analyst expectations. For the first six months of 2026, Axsome Therapeutics reported revenue of US$409.58 million and a net loss of US$115.86 million. Loss per share over this period was US$2.25 on both a basic and diluted basis. See our latest...

Axsome Therapeutics, Inc. Q2 shows 46% revenue growth as Auvelity expands, but SG&A surges and losses persist. Click to read why AXSM stock is a Sell.

Axsome Therapeutics (NASDAQ:AXSM) reported Q2 losses of 99 cents per share and sales of $218.4 million, missing analyst estimates. Analysts have mixed price targets for the stock.

Axsome Therapeutics has delivered a very large 5 year return while the current valuation checks point to a stock that now looks closer to fairly priced than clearly cheap. The market has rewarded the story, so the question is whether the present price still leaves enough room for longer term investors to be comfortable. Axsome Therapeutics has returned about 9.4x over the past 5 years, which puts the recent share price firmly at the higher end of its historical range for many...